Yair Lotan

2 months ago | urotoday.com | Yair Lotan

Read the Full Video TranscriptAshish Kamat: Hello, everyone, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, a urologic oncologist at MD Anderson Cancer Center.

2 months ago | urotoday.com | Yair Lotan

Read the Full Video TranscriptAshish Kamat: Hello, everybody, and welcome to UroToday's bladder Cancer Center of Excellence. I'm Ashish Kamat, urologic oncologist at M.D. Anderson Cancer Center. And it's a distinct pleasure to welcome once again, Professor Yair Lotan. He's a urologic oncologist at UT Southwestern in Dallas. Yair, thank you so much for taking the time today.

Jan 10, 2025 | onclive.com | Yair Lotan

CommentaryVideoJanuary 10, 2025Yair Lotan, MD, discusses the benefits and complications associated with radical cystectomy for patients with BCG-unresponsive NMIBC. “If a patient has the bladder removed when their cancer is noninvasive, their outcomes are superior to waiting until the cancer becomes invasive. Therefore, there is an opportunity to cure that patient.

Nov 5, 2024 | onclive.com | Yair Lotan

CommentaryVideoNovember 5, 2024Fact checked by:,Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer. Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C.

Oct 28, 2024 | onclive.com | Yair Lotan

CommentaryVideoOctober 28, 2024Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.